136 related articles for article (PubMed ID: 15457121)
1. Application of retinoids in the treatment of renal cell carcinoma--a futile effort?
Schrader AJ; von Knobloch R; Heidenreich A; Buer J; Hofmann R
Anticancer Drugs; 2004 Oct; 15(9):819-24. PubMed ID: 15457121
[TBL] [Abstract][Full Text] [Related]
2. Retinoids and metastatic renal cell carcinoma.
Paule B; Brion N
Ann Med Interne (Paris); 1997; 148(7):496-501. PubMed ID: 9538388
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of retinoids in cancer medicine.
Camacho LH
J Biol Regul Homeost Agents; 2003; 17(1):98-114. PubMed ID: 12757024
[TBL] [Abstract][Full Text] [Related]
4. Retinoid-interferon therapy of solid tumors.
Lippman SM; Lotan R; Schleuniger U
Int J Cancer; 1997 Feb; 70(4):481-3. PubMed ID: 9033661
[No Abstract] [Full Text] [Related]
5. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
[TBL] [Abstract][Full Text] [Related]
6. Axitinib for renal cell carcinoma.
Sonpavde G; Hutson TE; Rini BI
Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
[TBL] [Abstract][Full Text] [Related]
7. Retinoids in the treatment of acute promyelocytic leukemia. Review of the literature.
Graf N; Riesinger P; Reinhard H
Klin Padiatr; 1995; 207(2):43-7. PubMed ID: 7752598
[TBL] [Abstract][Full Text] [Related]
8. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
[TBL] [Abstract][Full Text] [Related]
9. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
10. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma.
Jaremtchuk AV; Aman EF; Ponce W; Zarbá JJ; Ferro AM; Alvarez R; Vigo SA
Am J Clin Oncol; 2002 Apr; 25(2):123-5. PubMed ID: 11943887
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid and interferon-alpha for treatment of human renal cell carcinoma multicellular tumor spheroids.
Rohde D; Brkovic D; Hönig d'Orville I
Urol Int; 2004; 73(1):47-53. PubMed ID: 15263793
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Vaishampayan U; Flaherty L; Du W; Hussain M
Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
14. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment.
Tavares TS; Nanus D; Yang XJ; Gudas LJ
Cancer Biol Ther; 2008 Oct; 7(10):1607-18. PubMed ID: 18769122
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
Yagoda A; Abi-Rached B; Petrylak D
Semin Oncol; 1995 Feb; 22(1):42-60. PubMed ID: 7855619
[No Abstract] [Full Text] [Related]
16. Predicting survival of patients with metastatic renal cell carcinoma.
Motzer RJ; Mazumdar M
Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
[TBL] [Abstract][Full Text] [Related]
17. Non-clear cell renal cancer: features and medical management.
Heng DY; Choueiri TK
J Natl Compr Canc Netw; 2009 Jun; 7(6):659-65. PubMed ID: 19555587
[TBL] [Abstract][Full Text] [Related]
18. The relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors.
Lenko V; Bialesova L; Macejova D; Bujdak P; Breza J; Brtko J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):316-24. PubMed ID: 24077234
[TBL] [Abstract][Full Text] [Related]
19. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
